Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the ...
・Company director Fitzgerald Alissa sold nearly 60,000 shares. ・Rigetti is one of several companies advancing quantum computing technologies aimed at solving complex problems in areas such as ...
In 2025, IonQ IONQ and Rigetti Computing RGTI gained the attention of investors tracking the rapid evolution of the quantum computing sector. Throughout the year, IonQ demonstrated accelerating ...